Horizon Pharma plc Announces 2016 Net Sales and Adjusted

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma plc Announces 2016 Net Sales and Adjusted EBITDA Guidance; Reviews 2020 Long-Range Plan

DUBLIN, IRELAND--(Marketwired - Nov 9, 2015) -

  • Full-Year 2016 Net Sales Guidance of $950 to $975 million 
  • Full-Year 2016 Adjusted EBITDA Guidance of $460 to $475 million 
  • 2020 Long-Range Plan Net Sales Estimated to Exceed $2 billion 
  • Long-Range Plan Estimates Orphan Business to Represent Approximately 60 percent of Net Sales in 2020 

Horizon Pharma plc ( NASDAQ : HZNP ), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, will host an investor meeting today where for the first time it is providing full-year 2016 net sales and adjusted EBITDA guidance and outlining its long-range plan for its current portfolio of medicines. The Company's presentation will begin at 11:30 a.m. EST and will be available via webcast at  http://ir.horizon-pharma.com/events.cfm .

"Since our Company's inception, we have built a strong and diversified portfolio of medicines through best-in-class commercial execution and value-enhancing acquisitions that we expect will drive nearly $1 billion in net sales in 2016," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "As we look to the future, we believe our long-range plan has the potential to double net sales by 2020, led by our rapidly expanding orphan business. We expect to accelerate clinical development of ACTIMMUNE, with a specific focus on Friedreich's ataxia and cancer."

Key Business Highlights

  • High-value, growing orphan business unit with current ACTIMMUNE and RAVICTI indications; significant growth opportunities with potential future indications
    • ACTIMMUNE and RAVICTI U.S. sales are currently annualizing at a $265 million run rate based on third quarter 2015 net sales.
    • Strong patent protection, including ACTIMMUNE through 2022 and RAVICTI through 2032 and additional long-term future growth opportunities:
      • ACTIMMUNE is in Phase 3 clinical development for Friedreich's ataxia with data expected by the end of 2016 and a potential regulatory decision in 2017.
      • ACTIMMUNE has potential in cancer with a Phase 1 dosing trial expected to initiate by year-end 2015:
        • Fox Chase Cancer Center collaboration to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer, including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma.
      • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion in September recommending a centralized marketing authorization for RAVICTI for use as an adjunctive therapy for Urea Cycle Disorders (UCDs). A marketing authorization decision by the European Commission is expected by the end of 2015 with a commercial launch anticipated in 2017, if approved.
    • Horizon's long-range plan anticipates its orphan business unit will represent approximately 60 percent of its total company net sales in 2020.
  • Primary care and specialty business units provide strong foundation for future growth
    • Horizon Pharma expects DUEXIS, VIMOVO, PENNSAID 2% and RAYOS to exceed $500 million in 2015 net sales and $800 million to $1 billion in 2020 net sales based on its long-range plan, driven by clinical differentiation and commercial execution, resulting in expected continued strong prescription growth.
    • Since January 2014, Horizon's total prescription growth for its primary care and specialty medicines has increased 189 percent, while the average net realized price for these medicines has increased approximately 16 percent.
    • DUEXIS, VIMOVO and PENNSAID 2% participate in the U.S. NSAID market, where 117 million prescriptions are written annually. The aggregate total prescription annual run rate for these three medicines is 1.5 million total prescriptions. This offers a significant opportunity for future growth.

Key Financial Highlights

  • On November 6, 2015, the company reported third-quarter 2015 results with net sales of $226.5 million, up more than 200 percent versus third quarter 2014 and adjusted EBITDA of $131.1 million, up nearly 500 percent versus third quarter 2014. The company also significantly increased its full-year 2015 net sales guidance to $750 to $760 million and adjusted EBITDA guidance to $350 to $360 million.
  • Providing first-time full-year 2016 net sales guidance of $950 to $975 million, which would represent more than 25 percent year-over-year growth at the midpoints of Horizon's 2015 and 2016 guidance ranges.
  • Providing first-time full-year 2016 adjusted EBITDA guidance of $460 to $475 million, which would represent more than 30 percent year-over-year growth at the midpoints of Horizon's 2015 and 2016 guidance ranges.
  • 2020 full-year net sales potential in long-range plan of more than $2 billion, which includes sales from ACTIMMUNE in Friedreich's ataxia, assuming approval for that indication.
  • If ACTIMMUNE is approved in selected cancer indications, based on the Company's long-range plan, it could present an additional net sales potential of $300 to $500 million in 2020.

About   Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit  www.horizonpharma.com . Follow  @HZNPplc  on Twitter or view careers on our  LinkedIn  page.

Note Regarding Use of Non-GAAP Financial Measures EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon as non-GAAP financial measures. Adjustments to EBITDA exclude acquisition transaction related expenses, loss on debt extinguishment, as well as non-cash items such as share-based compensation, depreciation and amortization, royalty accretion, non-cash interest expense, and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the company's expected 2015, 2016 and 2020 financial results and trends. In addition, these non-GAAP financial measures are among the indicators Horizon's management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon has not provided reconciliation of an expected adjusted EBITDA outlook to an expected net income (loss) outlook because certain items that are a component of net income (loss) cannot be reasonably projected, either due to the significant impact of changes in Horizon's stock price on share-based compensation, the variability associated with acquisition related expenses due to timing and other factors.

Forward-Looking Statements   This press release contains forward-looking statements, including, but not limited to, statements related to Horizon's expected full-year 2015 and 2016 net sales and adjusted EBITDA guidance, long-range plan net sales, adjusted EBITDA margin and product mix in 2020, expected financial performance in future periods, expected timing of clinical and regulatory events, Horizon Pharma's business strategy and plans, potential future indications for Horizon Pharma's existing products and other statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon's actual full-year 2015, 2016 or 2020 financial and operating results may differ from its expectations; Horizon Pharma's ability to grow net sales from existing products, successfully acquire additional products and increase the portion of net sales from its orphan business unit relative to its other business units; the availability of coverage and adequate reimbursement and pricing from government and third-party payors and risks relating to the success of Horizon's patient support program; risks associated with clinical development and regulatory approvals; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon Pharma operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon's filings and reports with the U.S. Securities and Exchange Commission ("SEC"). Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information.

Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations Investor-relations@horizonpharma.com Tina Ventura Vice President, Investor Relations Investor-relations@horizonpharma.com U.S. Media Contact: Geoff Curtis Group Vice President, Corporate Communications media@horizonpharma.com Ireland Media Contact: Ray Gordon Gordon MRM ray@gordonmrm.ie

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 83

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 84

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Funding Opportunity for Cartier Silver Corporation

Updated Category News Views 136

Cartier Silver Corporation Announces Financing Initiative Cartier Silver Corporation (CSE: CFE) has exciting news that emphasizes its commitment to growth and exploration. The Company is moving forward with a non-brokered private placement, intending to raise up to $1.5 million. Details of the Private Placement Under the terms of this Private Placement, Cartier Silver...

Continue Reading
Dynex Capital, Inc. Announces Exciting Dividend Updates

Updated Category News Views 56

Dynex Capital, Inc. Dividend Updates Dynex Capital, Inc. has recently made some important announcements regarding its dividends. The Board of Directors declared a cash dividend of $0.13 per share on its Common Stock (NYSE: DX) for September. Additionally, they revealed a quarterly cash dividend of $0.43125 per share for the 6.900% Series C Fixed-to-Floating Rate...

Continue Reading
Innovative Detox Solution to Alleviate Pain and Stress

Updated Category News Views 163

Introducing an Innovative Detox Solution In a world where wellness and self-care are becoming increasingly essential, an inventive product named TREETOX has emerged, aiming to redefine the way we think about detoxification and pain relief. Invented by a visionary in Pittsburgh, this product presents a seamless alternative for individuals battling ADHD and autism who are...

Continue Reading
WesBanco, Inc. Appoints Amby Bauer as Market President

Updated Category News Views 174

WesBanco, Inc. Names Amby Bauer as Western Pennsylvania Market President WesBanco, Inc. (NASDAQ: WSBC), a prominent multi-state banking institution, has announced the appointment of Amby Bauer as the new Western Pennsylvania Market President and Senior Commercial Banker. This strategic move comes at a time when the bank is focusing on enhancing its service provisions in...

Continue Reading
Svitzer Group Reports Major Shareholder Update from Morgan Stanley

Updated Category News Views 268

Svitzer Group Announces Major Shareholder Update In a significant development, Svitzer Group A/S has received a noteworthy notification concerning major shareholder dealings. The global leader in towage and marine services, Svitzer Group, confirmed a recent communication from Morgan Stanley regarding their shareholdings. As of a specified date, Morgan Stanley reportedly...

Continue Reading